Evidence map›Paper›PMID 38238027›Full record

Trial reportOpen heart2024

Use of sacubitril/valsartan early after CABG.

Madina Nurzhanova, Aisulu Musagaliyeva, Raushan Zhakypova, Daniya Senkibayeva, Amina Rakisheva

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open heart, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Madina NurzhanovaScientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.ORCID 0000-0003-2561-8707
Aisulu MusagaliyevaScientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.
Raushan ZhakypovaScientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.
Daniya SenkibayevaScientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.
Amina RakishevaScientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan amina.grakisheva@gmail.com.ORCID 0000-0001-9842-962X
Kazakhstan Medical University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart failure (HF) remains a major public health problem with a high mortality and morbidity worldwide. Currently, there is no optimal revascularisation strategy for patients with ischaemic cardiomyopathy despite suggestions that coronary artery bypass graft (CABG) may be superior to medical therapy in improving survival. However, CABG may be associated with substantial risk in HF subjects. We therefore aimed to evaluate the safety and efficacy of the early initiation of sacubitril/valsartan in haemodynamically stabilised patients with HF with reduced ejection fraction (HFrEF) after early CABG.

methodsThis was an open-label study in which ~80 patients after CABG were randomised either to the early or late initiation of the sacubitril-valsartan. The study included patients >40 years with left ventricular ejection fraction <45% and New York Heart Association (NYHA) class II-IV at the early stage after CABG. Patients underwent intervention, the starting dose of sacubitril/valsartan (24/26 mg or 49/51 mg two times per day). The follow-up took place every 4 weeks except the first visit, which took place in 2 weeks after initiation. The primary endpoint assessed the key safety outcomes, the secondary endpoints were: the quality of life measured, the N-terminal pro-B-type natriuretic peptide (NT-proBNP) changes and 6 min walk test (6MWT).

resultsIn total, 83 patients were screened and 77 patients were enrolled. The majority of patients (84.4%) were in the NYHA class III at randomisation. The number of patients who discontinued the study was low in both groups (2.5%, 5.2%), and renal function, hyperkalaemia and symptomatic hypotension rarely seen in both groups did not differ significantly. The improvement in quality of life and distance at the 6MWT in both groups was significant (p<0.001). The NT-proBNP concentration decreased in both groups, the significant reduction was in the early group (p<0.001) versus the postdischarge group.

conclusionsThe early initiation of sacubitril/valsartan in patients after CABG with HFrEF is safe and effective. Adverse events and permanent discontinuation were low. The NT-proBNP concentration reduced significantly with the early in-hospital initiation.

Indexed as

AminobutyratesBiphenyl CompoundsHeart FailureAftercareCoronary Artery BypassDrug CombinationsHumansPatient DischargeQuality of LifeStroke VolumeTetrazolesValsartanVentricular Function, LeftAminobutyratesBiphenyl CompoundsDrug Combinationssacubitrilsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanCoronary Artery BypassCoronary Artery DiseaseHeart FailurePharmacology, Clinical

Identifiers

PMID38238027
PMCPMC10806467
OpenAlexW4390988210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.